Free delivery over $3201–3 day express deliveryDispatched Australia-wideIndependent lab reports published
Free bac water with any 2 vials · no code · ends Thu 26 NovBlack Fridayopens Fri 27 Nov ·  
Shop now

CJC-1295 no DAC + ipamorelin – 10mg

$90.00

CJC-1295 No DAC + Ipamorelin 10mg is an experimental two-peptide blend associated with GHRH receptor signalling, GHSR1a receptor pharmacology and endocrine pathway research.

Available from Peps Aussie Australia for controlled laboratory research and analytical applications.

  • Product: CJC-1295 No DAC + Ipamorelin
  • Total Labelled Size: 10mg
  • Material Type: Two-peptide research blend
  • Component 1: CJC-1295 No DAC — GHRH-related analogue
  • Component 2: Ipamorelin — GHSR1a receptor agonist
  • Research Areas: GHRH signalling, ghrelin receptor pharmacology and endocrine pathway interactions
  • Component Ratio: Not specified; requires lot-specific verification
  • Quality Documentation: Available Certificates of Analysis (COA)
  • Shipping: Australian dispatch, subject to stock availability
  • Intended Use: Scientific and laboratory research only

The 10mg label refers to the combined quantity and does not establish a 5mg + 5mg split.

For laboratory research use only. Not intended for human or animal consumption, administration, bodybuilding or therapeutic use.

Free Delivery on all orders above $320

Out of stock

Description

CJC-1295 No DAC + Ipamorelin 10mg – Dual Receptor Research Peptide Blend Australia

CJC-1295 No DAC + Ipamorelin 10mg is an experimental two-peptide research blend listed by Peps Aussie Australia as reference material for scientific investigation, laboratory analysis and controlled endocrine research.

The formulation is described as containing two synthetic peptides associated with different receptor systems involved in growth hormone regulation.

CJC-1295 No DAC is a commercial designation commonly associated with a modified growth-hormone-releasing hormone (GHRH) analogue.

Ipamorelin is a synthetic pentapeptide investigated as an agonist of the growth hormone secretagogue receptor type 1a (GHSR1a), also known as the ghrelin receptor.

These receptor systems participate in endocrine signalling through distinct molecular mechanisms.

GHRH receptor activation is associated with hypothalamic–pituitary signalling, while GHSR1a activation is associated with ghrelin-related endocrine pathways.

The combination provides a subject for experimental investigation into receptor-specific signalling and potential interactions between these pathways.

However, research involving the individual peptides does not establish that the combined formulation produces additive, synergistic or clinically beneficial effects.

Combination-specific evidence is limited, and any experimental interpretation requires verification of both peptide identities, their relative quantities and the analytical characteristics of the blend.

Peps Aussie lists CJC-1295 No DAC + Ipamorelin in a nominal total size of 10mg.

The 10mg designation refers to the combined labelled quantity and does not independently establish the amount of either individual peptide.

Important: CJC-1295 No DAC + Ipamorelin is intended strictly for laboratory research and analytical purposes. It is not supplied for human or animal consumption, injection, administration, bodybuilding, performance enhancement, therapeutic use or clinical treatment.

What Is CJC-1295 No DAC + Ipamorelin?

CJC-1295 No DAC + Ipamorelin is a research blend described as containing two synthetic peptides associated with growth hormone-related endocrine signalling.

The components are chemically and pharmacologically distinct.

CJC-1295 No DAC

CJC-1295 No DAC is a commercial name frequently associated with Modified GRF(1–29), a synthetic analogue derived from the first 29 amino acid residues of human growth-hormone-releasing hormone.

The designation No DAC indicates that the peptide is described as lacking the drug-affinity-complex modification associated with certain CJC-1295 preparations.

However, the commercial designation does not establish a unique molecular identity without sequence verification.

The precise peptide sequence, substitutions, terminal modifications and absence of DAC should be confirmed through analytical documentation.

Ipamorelin

Ipamorelin is a synthetic pentapeptide investigated as an agonist of the growth hormone secretagogue receptor type 1a (GHSR1a).

This receptor is also commonly known as the ghrelin receptor.

Ipamorelin is chemically distinct from GHRH analogues and has been studied in relation to receptor selectivity and growth hormone-associated endocrine responses.

Why Are These Peptides Studied Together?

The two peptides are associated with different receptor pathways involved in endocrine regulation.

This creates research questions involving:

  • GHRH receptor signalling.
  • GHSR1a receptor signalling.
  • Comparative receptor pharmacology.
  • Endocrine pathway interactions.
  • Experimental pituitary physiology.
  • Combined peptide analytical characterisation.
  • Receptor-specific response measurements.

These are potential areas of laboratory investigation, not evidence of established combination benefits.

CJC-1295 No DAC + Ipamorelin Research and Scientific Applications

Research involving GHRH analogues and growth hormone secretagogues spans receptor pharmacology, endocrine physiology, peptide chemistry and experimental signalling.

The following sections describe relevant scientific research topics rather than demonstrated effects of the Peps Aussie blend.

1. GHRH Receptor Signalling Research

The growth-hormone-releasing hormone receptor (GHRHR) is a G protein-coupled receptor involved in pituitary endocrine regulation.

Synthetic GHRH analogues are investigated for their interaction with this receptor.

Relevant research topics include:

  • GHRH receptor activation.
  • Ligand–receptor interactions.
  • Receptor-associated signalling.
  • Intracellular second messenger pathways.
  • Experimental endocrine models.
  • Concentration–response relationships.
  • Comparative peptide pharmacology.

These investigations contribute to understanding GHRH receptor biology.

However, published findings involving DAC-containing CJC-1295 do not automatically apply to material described as CJC-1295 No DAC.

2. GHSR1a and Ghrelin Receptor Research

The growth hormone secretagogue receptor type 1a is associated with ghrelin-related endocrine signalling.

Ipamorelin has been investigated as a synthetic agonist of this receptor.

Relevant research topics include:

  • GHSR1a receptor activation.
  • Ghrelin receptor pharmacology.
  • Ligand-dependent signalling.
  • Intracellular regulatory pathways.
  • Receptor selectivity.
  • Experimental cellular assays.
  • Comparative secretagogue research.

These investigations contribute to understanding the molecular characteristics of growth hormone secretagogue receptor agonists.

However, receptor activity observed with Ipamorelin alone does not establish the activity of a combined peptide preparation.

3. Pituitary Growth Hormone Signalling Research

Growth hormone is a peptide hormone released by the anterior pituitary gland.

Its secretion is regulated through several interacting endocrine pathways.

GHRH receptor signalling and GHSR1a-associated pathways are both relevant to experimental research involving growth hormone regulation.

Relevant scientific topics include:

  • Pituitary endocrine physiology.
  • Growth hormone-associated signalling.
  • Hypothalamic–pituitary interactions.
  • Hormone-associated measurements.
  • Receptor-mediated responses.
  • Experimental endocrine feedback.
  • Comparative secretagogue pharmacology.

These investigations contribute to understanding endocrine regulation.

However, the presence of two receptor-associated peptides does not establish a predictable combined hormonal response.

4. Dual Receptor Pathway Research

One reason researchers may investigate GHRH-related peptides alongside GHSR1a agonists is the involvement of two distinct receptor systems.

Experimental questions may involve how different receptor pathways contribute to cellular or endocrine responses.

Relevant research topics include:

  • Receptor-specific signalling.
  • Parallel endocrine pathways.
  • Cellular response measurements.
  • Comparative receptor activation.
  • Intracellular signalling.
  • Experimental pathway interactions.
  • Pharmacological assay design.

These investigations may help researchers understand how distinct signalling systems interact.

However, dual receptor activity does not automatically demonstrate pharmacological synergy.

Synergy requires direct experimental evidence using an appropriate comparison of the individual components and their combination.

5. Endocrine Feedback and Hormone Regulation Research

The growth hormone axis involves interactions between hypothalamic signalling, pituitary hormone secretion and downstream endocrine processes.

GHRH-related peptides and ghrelin receptor agonists are investigated within this broader physiological context.

Relevant research topics include:

  • Hypothalamic–pituitary regulation.
  • Growth hormone-associated biomarkers.
  • Endocrine feedback mechanisms.
  • Receptor-mediated signalling.
  • Hormone-associated response profiles.
  • Experimental endocrine models.

These investigations provide context for understanding the regulatory systems associated with the two peptides.

However, changes in endocrine biomarkers are not inherently beneficial and cannot independently establish therapeutic efficacy.

6. Peptide Combination and Interaction Research

Combination research examines how two or more compounds behave when studied together.

For peptide blends, experimental interpretation requires consideration of each component’s identity, quantity and chemical characteristics.

Relevant research topics include:

  • Individual versus combined responses.
  • Receptor-specific activity.
  • Potential pharmacological interactions.
  • Component concentration ratios.
  • Experimental assay conditions.
  • Peptide compatibility.
  • Analytical interference.

These investigations may contribute to understanding how different research peptides behave in combination.

However, combination-specific findings cannot be assumed from studies involving either component individually.

7. CJC-1295 No DAC + Ipamorelin Compared With Individual Peptides

The combined product should be distinguished from its individual components and other growth hormone-related peptides.

CJC-1295 No DAC:

  • Commonly associated with Modified GRF(1–29).
  • Investigated in the context of GHRH receptor signalling.
  • Described as lacking a DAC modification.
  • Requires verification of its exact sequence.

Ipamorelin:

  • A synthetic pentapeptide.
  • Investigated as a GHSR1a receptor agonist.
  • Associated with growth hormone secretagogue pharmacology.
  • Has a distinct molecular structure and receptor mechanism.

CJC-1295 No DAC + Ipamorelin Blend:

  • Contains two separately identified peptide components.
  • Is associated with two different receptor pathways.
  • Requires verification of each component’s identity.
  • Requires confirmation of the amount of each component.
  • Does not have established clinical safety or efficacy as a combined research preparation.

Research findings involving one component should not automatically be attributed to the blend.

8. Combination Analytical Characterisation and Quality Research

Analytical characterisation is particularly important for research blends containing more than one peptide.

Laboratories evaluating CJC-1295 No DAC + Ipamorelin may investigate:

  • Confirmation of both peptide identities.
  • Verification of the CJC-1295 No DAC amino acid sequence.
  • Confirmation of the absence of DAC.
  • Verification of the Ipamorelin sequence.
  • Molecular mass determination for each component.
  • Quantitative content of each peptide.
  • Relative component proportions.
  • Chromatographic separation.
  • Related peptide impurities.
  • Stability and degradation characteristics.
  • Batch-to-batch analytical consistency.

Analytical techniques may include high-performance liquid chromatography (HPLC), mass spectrometry (MS) and other suitable methods.

A single total purity result does not independently establish the identity, quantity or purity of each individual component.

Likewise, a total 10mg label does not establish that the blend contains 5mg of each peptide.

CJC-1295 No DAC + Ipamorelin 10mg Research Blend Specifications

Peps Aussie lists CJC-1295 No DAC + Ipamorelin in a nominal 10mg total size.

Specification Details
Product name CJC-1295 No DAC + Ipamorelin
Listed total size 10mg
Material type Experimental two-peptide blend
Component 1 CJC-1295 No DAC
Component 2 Ipamorelin
Component 1 research association GHRH receptor signalling
Component 2 research association GHSR1a receptor signalling
Individual component quantities Require verification
Blend ratio Not specified; requires verification
CJC-1295 No DAC sequence Requires verification
Ipamorelin sequence Requires verification against lot documentation
Research category Endocrine receptor pharmacology
Research areas GHRH signalling, GHSR1a signalling and experimental pathway interactions
Supplier Peps Aussie Australia
Intended use Laboratory research and analytical investigation only

Important: The 10mg designation refers to the total labelled blend strength. It does not establish the individual quantities or proportions of CJC-1295 No DAC and Ipamorelin.

The exact molecular identity, amino acid sequence, terminal modifications, salt form, formulation, physical appearance, fill quantity and excipients of each component should be confirmed against the applicable product label and supporting lot documentation.

CJC-1295 No DAC + Ipamorelin Certificate of Analysis (COA) and Quality Documentation

Analytical verification is especially important when evaluating research materials containing multiple peptide components.

Peps Aussie maintains a dedicated resource where researchers can review available Certificates of Analysis and supporting analytical records.

View Peps Aussie Certificates of Analysis

When evaluating this blend’s analytical documentation, researchers should consider:

  • Component identity: Whether both declared peptides have been identified.
  • Sequence verification: Whether each peptide’s molecular structure has been established.
  • DAC status: Whether the absence of the DAC modification is supported.
  • Individual content: Whether the amount of each peptide has been quantified.
  • Blend ratio: Whether the relative proportion of the two components has been established.
  • Purity assessment: Whether the analytical method can appropriately distinguish the components and their impurities.
  • Total content: Whether quantitative testing supports the declared 10mg total quantity.
  • Batch traceability: Whether the certificate corresponds to the supplied production lot.
  • Testing methodology: Whether the analytical techniques are suitable for a multi-component peptide preparation.
  • Additional testing: Whether relevant contamination or other quality assessments were performed.

High-performance liquid chromatography and mass spectrometry may support peptide characterisation.

However, a certificate reporting a combined or general purity result does not automatically establish the individual identity, purity or content of both components.

A certificate should be interpreted according to the tests actually performed.

The availability of a certificate does not automatically establish sterility, endotoxin status, a particular purity percentage, pharmaceutical-grade manufacturing or independent verification of every production batch.

CJC-1295 No DAC + Ipamorelin Storage and Laboratory Handling

Multi-component peptide research materials require appropriate handling to support sample integrity and experimental reproducibility.

Storage requirements depend on the molecular structures, formulation, packaging and validated manufacturer stability information.

Laboratories should consider:

  • Appropriate storage temperature.
  • Protection from light and moisture where necessary.
  • Suitable laboratory containers.
  • Compatibility with analytical solvents.
  • Potential interactions between the two components.
  • Stability following sample preparation.
  • Potential degradation during storage.
  • Appropriate laboratory handling and disposal procedures.

No universal storage temperature or reconstitution procedure is recommended without verified product-specific documentation.

Storage information for the individual peptides should not automatically be applied to a combined preparation.

All laboratory work should be performed by appropriately qualified personnel using validated procedures and suitable safety controls.

CJC-1295 No DAC + Ipamorelin 10mg Australia – Product Availability and Shipping

Peps Aussie maintains an Australian-based catalogue of research peptides and laboratory materials for scientific and analytical applications.

CJC-1295 No DAC + Ipamorelin 10mg is the currently listed nominal product size.

The 10mg designation refers to the combined labelled quantity, not a verified individual component split.

Pricing and ordering availability should be confirmed through the product selection area. Inventory is currently pending confirmation.

For current information regarding Australian dispatch, delivery arrangements, processing times and applicable restrictions, visit the Peps Aussie Shipping Policy.

Frequently Asked Questions About CJC-1295 No DAC + Ipamorelin

What is CJC-1295 No DAC + Ipamorelin?

It is an experimental research blend described as containing a GHRH-related peptide and Ipamorelin, a GHSR1a receptor agonist.

What is the blend studied for?

Relevant laboratory research topics include GHRH receptor signalling, GHSR1a receptor pharmacology, pituitary endocrine physiology and potential interactions between receptor pathways.

What does 10mg mean for this blend?

The 10mg designation refers to the total labelled quantity of the combined product. It does not specify how much of each peptide is present.

Does the blend contain 5mg CJC-1295 No DAC and 5mg Ipamorelin?

That cannot be assumed. The amount of each component must be confirmed through the product label and applicable lot-specific documentation.

Do CJC-1295 No DAC and Ipamorelin activate the same receptor?

No. CJC-1295 No DAC is associated with GHRH receptor signalling, while Ipamorelin is investigated as an agonist of GHSR1a.

Is CJC-1295 No DAC the same as Modified GRF(1–29)?

The names are frequently used interchangeably in commercial settings, but chemical equivalence requires verification of the amino acid sequence and molecular modifications.

Is the blend the same as CJC-1295 With DAC + Ipamorelin?

No. DAC-containing CJC-1295 is a different molecular form. Findings involving DAC-containing preparations should not automatically be applied to non-DAC blends.

Does combining the peptides create a synergistic effect?

Synergy has not been established for the Peps Aussie research material. Demonstrating synergy requires direct combination-specific experimental evidence.

Does the blend increase growth hormone?

The individual receptor systems are associated with growth hormone-related endocrine signalling. However, this does not establish a predictable combined hormonal response or clinical benefit from the supplied blend.

Is the blend studied for muscle growth or fat loss?

Growth hormone-related pathways are investigated in endocrine and metabolic research, but there is insufficient evidence to establish that this research blend safely or effectively increases muscle mass or reduces body fat in humans.

What size does Peps Aussie list?

Peps Aussie lists the combined product in a 10mg nominal total size.

Does the blend have a Certificate of Analysis?

Available analytical documentation can be reviewed through the Peps Aussie Certificates of Analysis page. Researchers should verify the lot number and whether testing identifies and quantifies both components.

How should the blend be stored?

Storage requirements depend on the formulation and validated stability characteristics of the combined material. Follow the manufacturer’s product-specific documentation and established laboratory procedures.

Is CJC-1295 No DAC + Ipamorelin approved for human or veterinary use?

No medical or veterinary approval is claimed for the Peps Aussie research blend.

It is not supplied for human or animal consumption, administration, diagnosis, prevention or treatment.

CJC-1295 No DAC + Ipamorelin Research Blends at Peps Aussie Australia

Peps Aussie maintains a catalogue of laboratory research peptides and scientific materials for researchers investigating molecular biology, peptide chemistry and endocrine signalling.

CJC-1295 No DAC + Ipamorelin is relevant to research discussions involving GHRH receptor pharmacology, GHSR1a signalling and experimental endocrine pathway interactions.

Researchers evaluating the 10mg blend should prioritise accurate identification of both components, verification of their individual quantities, appropriate analytical documentation, batch traceability and validated laboratory procedures.

Explore the Peps Aussie research catalogue at pepsaussie.com.


Research Use Only Disclaimer

CJC-1295 No DAC + Ipamorelin 10mg is intended strictly for laboratory research and analytical purposes only.

This product is not intended for human or animal consumption, injection, administration, bodybuilding, performance enhancement, therapeutic use or clinical treatment.

Descriptions of published scientific research are provided for educational and informational purposes only. They do not establish muscle growth, fat loss, recovery enhancement, anti-ageing benefits, growth hormone optimisation, clinical safety or therapeutic suitability for the material offered.

Research findings involving the individual peptides or DAC-containing CJC-1295 should not be assumed to apply to this combined preparation without verified chemical identity, component quantities and direct supporting evidence.

No dosing, self-administration or therapeutic guidance is provided.

Additional information

Size

10mg

Reviews

There are no reviews yet.

Reviews here are by invitation. We email a link once your order has arrived, so every review comes from someone who received the product. Lost the email? Find your review link.

Related Products

Search Products